Drug Database
Back to search

Netherlands· NL-a41d24931112

IMBRUVICA 140 mg, harde capsules

A ibrutinib product containing ibrutinib, registered in Netherlands by Janssen-Cilag International NV. The same ATC class is registered in 13 of our 19 countries.

ATC L01EL01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedIMBRUVICA 140 mg, harde capsulesATCL01EL01REGISTER NO.NL-a41d24931112PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ibrutinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ibrutinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EL01 (ibrutinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search ibrutinib products by name

Ibrutinib · ATC L01EL01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ibrutinib costs, country by country.

Normalised to the WHO defined daily dose (0.42 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ibrutinib · price per daily dose (0.42 g)

USD · FX 28 Sept 2026

  • CH Switzerland$193.73
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
IBRUTINIB
Manufacturer
Janssen-Cilag International NV
Country
Netherlands (NL)
ATC code
L01EL01
ATC class
Ibrutinib
Defined daily dose
0.42 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/945

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

370 interactions on record for ibrutinib.

Graded by severity as the source publishes them — 189 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ibrutinib against other medicinesHow interaction checks work

Ibrutinib · interactions on record

370 records

  • 189 severe
  • 177 moderate
  • 4 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • LinseedA06AC05severe
  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ibrutinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ibrutinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Imbruvica
  • Liechtenstein · Imbruvica
  • Norway · Imbruvica

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7072cb76-c9aa-48bc-b8f8-83717fa54970
GET /v1/drugs/7072cb76-c9aa-48bc-b8f8-83717fa54970?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ibrutinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp114660",
  "excipients": [
    "AMMONIA (E 527)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GELATINE (E 441)",
    "IJZEROXIDE ZWART (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "IBRUTINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/10/17",
  "procedure_number": "EMEA/H/C/003791",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/945",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about ibrutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console